Literature DB >> 7815348

Vasorelaxant and second messenger effects of maxadilan.

S A Grevelink1, J Osborne, J Loscalzo, E A Lerner.   

Abstract

Maxadilan is a potent vasodilator isolated from salivary gland extracts of the sand fly. Although cutaneous vasodilatation is probably the most important physiologic effect of maxadilan (i.e., assisting the sand fly in obtaining a blood meal), it also has effects on other vascular beds. In rabbit isolated aorta, recombinant maxadilan exhibited endothelium-independent relaxations with an IC50 of 24 nM for norepinephrine-induced (1 microM) contractions. Synthetic maxadilan had one-third the potency, with a corresponding IC50 of 74 nM for norepinephrine-induced (1 microM) contractions. Pretreatment with a number of receptor and channel blockers, including tetraethylammonium (1 mM), glyburide (1 microM), barium (0.5 mM), indomethacin (10 microM), propranolol (10 microM), cimetidine (10 microM) and nifedipine (10 microM) did not affect maxadilan-induced relaxations. After treatment with maxadilan, contractions recurred very slowly over approximately 40 min. At a concentration of 1 microM, maxadilan induced a 2- to 3-fold increase in cellular cyclic AMP levels. Maxadilan's activity was selective according to vessel type, with maximal activity in rabbit aorta and mesenteric artery and no activity in porcine and bovine coronary arteries. These studies suggest that maxadilan acts by raising the intracellular levels of cyclic AMP in the smooth muscle of selected blood vessels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815348

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Maxadilan, a PAC1 receptor agonist from sand flies.

Authors:  Ethan A Lerner; Aurel O Iuga; Vemuri B Reddy
Journal:  Peptides       Date:  2007-06-28       Impact factor: 3.750

2.  Activation of PAC(1) and VPAC receptor subtypes elicits differential physiological responses from sympathetic preganglionic neurons in the anaesthetized rat.

Authors:  Melissa A Inglott; Ethan A Lerner; Paul M Pilowsky; Melissa M J Farnham
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration.

Authors:  A Vaczy; D Reglodi; T Somoskeoy; K Kovacs; E Lokos; E Szabo; A Tamas; T Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

4.  Sand fly saliva enhances Leishmania amazonensis infection by modulating interleukin-10 production.

Authors:  Nilufer B Norsworthy; Jiaren Sun; Dia Elnaiem; Gregory Lanzaro; Lynn Soong
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 5.  Maxadilan, the PAC1 receptor, and leishmaniasis.

Authors:  Vemuri B Reddy; Yhong Li; Ethan A Lerner
Journal:  J Mol Neurosci       Date:  2008-05-29       Impact factor: 3.444

6.  Functional transcriptomics of wild-caught Lutzomyia intermedia salivary glands: identification of a protective salivary protein against Leishmania braziliensis infection.

Authors:  Tatiana R de Moura; Fabiano Oliveira; Marcia W Carneiro; José Carlos Miranda; Jorge Clarêncio; Manoel Barral-Netto; Cláudia Brodskyn; Aldina Barral; José M C Ribeiro; Jesus G Valenzuela; Camila I de Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2013-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.